Provided by Tiger Trade Technology Pte. Ltd.

INCANNEX HEALTHCARE LTD

0.3966
+0.042912.13%
Post-market: 0.39880.0022+0.55%17:08 EST
Volume:23.60M
Turnover:9.09M
Market Cap:138.02M
PE:-0.89
High:0.4090
Open:0.3683
Low:0.3580
Close:0.3537
52wk High:2.25
52wk Low:0.0800
Shares:348.00M
Float Shares:89.88M
Volume Ratio:2.76
T/O Rate:26.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4448
EPS(LYR):-1.3608
ROE:-114.52%
ROA:-30.33%
PB:1.79
PE(LYR):-0.29

Loading ...

Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea

Reuters
·
Nov 20

Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and Eoy 2025 Strategic Focus

THOMSON REUTERS
·
Oct 30

Incannex Healthcare Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Reuters
·
Oct 28

BRIEF-Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Reuters
·
Oct 22

Incannex Healthcare Faces Nasdaq Delisting Risk Over Low Share Price

Reuters
·
Oct 22

Incannex Healthcare Reports Fiscal 2025 Revenue Up 617% to $86,000; Net Loss Widens to $46.9 Million

Reuters
·
Sep 30

US Listed Shares of Incannex Healthcare Rise 18.7% After Co's Anxiety Treatment Meets Mid-Stage Trial Goal

THOMSON REUTERS
·
Aug 26

Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder

Reuters
·
Aug 26

Incannex Healthcare Inc - PSI-Gad Treatment Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Aug 26

Incannex Healthcare: Phase 2 PSI-Gad Trial Shows Significant Improvements Across All Primary & Secondary Endpoints

THOMSON REUTERS
·
Aug 26

Incannex Healthcare Inc - Psx-001 Shows Significant Improvements in Gad Treatment

THOMSON REUTERS
·
Aug 26

Incannex Reports Positive Results From Phase 2 Clinical Trial of Psx-001 (PSI-Gad) for Generalised Anxiety Disorder

THOMSON REUTERS
·
Aug 26

Top Midday Gainers

MT Newswires Live
·
Aug 23

Incannex Healthcare Shares Rise 32.8% Premarket on $20 Million Share Repurchase Program

THOMSON REUTERS
·
Aug 22

BUZZ-Incannex Healthcare jumps on $20 million share repurchase program

Reuters
·
Aug 22

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

THOMSON REUTERS
·
Aug 22

Stonegate Updates Coverage: Incannex Healthcare Achieves Significant Progress with IHL-42X in Phase 2 Trial

Reuters
·
Aug 20

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for Ihl-42X in Obstructive Sleep Apnoea

THOMSON REUTERS
·
Aug 08

Incannex Healthcare Inc - 57.6% Participants Report Improvement in Obstructive Sleep Apnoea

THOMSON REUTERS
·
Aug 08

Incannex Healthcare Inc - Ihl-42X Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Aug 08